Why did Boston Scientific's Q2 2026 results beat guidance while full-year sales guidance is only 5.5%–6.5%?

Q2 reported sales growth of 7.5% exceeded the company's 5.5%–7.5% guidance range, and organic growth of 7.0% topped the 5%–7% range. However, the Q3 outlook of 3%–5% growth and the full-year range imply a deceleration in the second half, which the company has not fully explained in this release. Investors should review the earnings call for management's commentary on the drivers of that slowdown.

How much of the EPS improvement is driven by share buybacks and other items?

Diluted weighted-average shares fell to 1,474.8 million from 1,493.5 million, reflecting the completed $2B accelerated share repurchase. Adjusted EPS rose to $0.86 from $0.75, but the release does not break out how much of that increase is attributable to the lower share count versus operating performance.

What are the main risks flagged in this filing?

The release highlights a $76M litigation-related net charge in Q2, ongoing exposure to foreign currency (which reduced reported growth by 0.5 points in Q2 and is expected to reduce full-year reported growth by about 0.5 points), and the uncertain impact of tariff policy, reflected in a tariff refund benefit. The forward-looking statements also cite competition, reimbursement, clinical trial outcomes, and supply chain disruption.

What is the strategic significance of the $1.5B MiRus investment?

The investment gives Boston Scientific an approximately 34% equity stake in MiRus LLC, which develops the SIEGEL balloon-expandable TAVR system, and an exclusive option to acquire the MiRus TAVR business. This provides a potential entry into the TAVR market, but the SIEGEL system is investigational and not available for sale, so commercial impact is likely years away and contingent on regulatory approval and the exercise of the option.

Are the new clinical programs likely to drive near-term revenue?

Probably not in the near term. The SEISMIQ 4CE coronary lithotripsy catheter, the FARAFLEX mapping and PFA catheter, and the SIEGEL TAVR system are all investigational devices limited to investigational use in the U.S. The FARAPULSE data from AVANT GUARD and the FARADIGM enrollment support the long-term pipeline in atrial fibrillation, but revenue contribution will depend on future regulatory approvals.

BSX 8-K: Earnings & Results

01—Abstract

Summary

Summary of the 8-K filed July 29, 2026. Cited figures are marked; the original filing is the authoritative source.

Boston Scientific (BSX) reported second-quarter 2026 net sales of $5.442 billion^a, up 7.5% on a reported basis and 7.0% on an operational and organic basis versus the prior year.

Growth was driven by Cardiovascular (up 8.3% reported, 7.8% organic) and MedSurg (up 5.9% reported, 5.4% organic). Regionally, Latin America and Canada (up 22.4% reported, 16.2% operational) and Asia-Pacific (up 11.2%) led, while the U.S. grew 6.2% and EMEA 4.2% on an operational basis. Adjusted EPS of $0.86^b beat the company's $0.82 to $0.84 guidance range, and GAAP diluted EPS was $0.61 versus $0.53 a year ago.

GAAP results were affected by a $76 million^c litigation-related charge and adjustments for IEEPA tariff refunds and deferred tax items. The company lowered its full-year 2026 outlook to reported net sales growth of 5.5% to 6.5% (5% to 6% organic) and adjusted EPS of $3.28 to $3.32. Third-quarter guidance calls for 3% to 5% sales growth and adjusted EPS of $0.80 to $0.82.

Management described the environment as dynamic and emphasized prioritizing investments in its highest-impact opportunities. Capital allocation included completing a $2 billion^d accelerated share repurchase (about 40 million shares retired) and a $1.5 billion investment in MiRus LLC for roughly a 34% equity stake and an exclusive option to acquire its TAVR business. Clinical and pipeline news was active, including FRACTURE IDE trial data for the SEISMIQ coronary lithotripsy catheter, AVANT GUARD data supporting FARAPULSE in first-line persistent AF, and enrollment start in the pivotal FARADIGM trial for the FARAFLEX mapping and PFA catheter.

Several of these products remain investigational and are not yet available for sale. Investors will likely focus on whether the reduced full-year guidance reflects softness in the second half and on the durability of growth in the core electrophysiology and cardiovascular franchises.

02—Key points

Key Highlights

Q2 2026 net sales of $5.442B grew 7.5% reported and 7.0% organic, ahead of the company's guidance ranges of 5.5%–7.5% reported and 5%–7% organic.
Adjusted EPS of $0.86 beat the $0.82–$0.84 guidance range; GAAP diluted EPS rose to $0.61 from $0.53.
Full-year 2026 guidance was set at 5.5%–6.5% reported sales growth and adjusted EPS of $3.28–$3.32; Q3 guidance of 3%–5% sales growth and $0.80–$0.82 adjusted EPS points to a slower second half.
Cardiovascular (+8.3% reported) outperformed MedSurg (+5.9%), with Neuromodulation (+12.7%) the fastest-growing business within MedSurg.
Latin America and Canada (+22.4% reported) and Asia-Pacific (+11.2%) were the strongest regions; EMEA operational growth slowed to 4.2%.
Completed a $2B accelerated share repurchase (~40 million shares) and invested $1.5B for a ~34% stake in MiRus LLC with an option to acquire its SIEGEL TAVR business.
A $76M litigation-related charge and a $(83)M IEEPA tariff refund affected GAAP results, and GAAP net income includes a $70M deferred tax expense in Q2 that is excluded from adjusted figures.

03—Questions

Frequently Asked Questions

Why did Boston Scientific's Q2 2026 results beat guidance while full-year sales guidance is only 5.5%–6.5%?
Q2 reported sales growth of 7.5% exceeded the company's 5.5%–7.5% guidance range, and organic growth of 7.0% topped the 5%–7% range. However, the Q3 outlook of 3%–5% growth and the full-year range imply a deceleration in the second half, which the company has not fully explained in this release. Investors should review the earnings call for management's commentary on the drivers of that slowdown.
How much of the EPS improvement is driven by share buybacks and other items?
Diluted weighted-average shares fell to 1,474.8 million from 1,493.5 million, reflecting the completed $2B accelerated share repurchase. Adjusted EPS rose to $0.86 from $0.75, but the release does not break out how much of that increase is attributable to the lower share count versus operating performance.
What are the main risks flagged in this filing?
The release highlights a $76M litigation-related net charge in Q2, ongoing exposure to foreign currency (which reduced reported growth by 0.5 points in Q2 and is expected to reduce full-year reported growth by about 0.5 points), and the uncertain impact of tariff policy, reflected in a tariff refund benefit. The forward-looking statements also cite competition, reimbursement, clinical trial outcomes, and supply chain disruption.
What is the strategic significance of the $1.5B MiRus investment?
The investment gives Boston Scientific an approximately 34% equity stake in MiRus LLC, which develops the SIEGEL balloon-expandable TAVR system, and an exclusive option to acquire the MiRus TAVR business. This provides a potential entry into the TAVR market, but the SIEGEL system is investigational and not available for sale, so commercial impact is likely years away and contingent on regulatory approval and the exercise of the option.
Are the new clinical programs likely to drive near-term revenue?
Probably not in the near term. The SEISMIQ 4CE coronary lithotripsy catheter, the FARAFLEX mapping and PFA catheter, and the SIEGEL TAVR system are all investigational devices limited to investigational use in the U.S. The FARAPULSE data from AVANT GUARD and the FARADIGM enrollment support the long-term pipeline in atrial fibrillation, but revenue contribution will depend on future regulatory approvals.

04—Continue

← View all 8-K filings